In 1998, that has resulted in various drugs normally used in transplant treatment being applied in rheumatic disorders cyclosporin.
These drugs, called Cox 2 inhibitors, are likely to be marketed to people with rheumatoid arthritis (RA) and osteoarthritis or nearly 40 million Americans.
Pain sufferers may be getting some new drug options that appear to bring relief with fewer side effects than most other treatments.
The drug works as well and probably better than other treatments for neuropathic pain, but with far fewer side effects.
In 1999, Merck spokesman John Bloomfield refused to speculate whether the company has enough research results to get a better warning label than Monsanto.
Celebrex, approved for osteoarthritis and RA, has already sold more than 1.1 million prescriptions, making it the biggest new drug of 1999.
Like Celebrex, Merck is looking to get approval for Vioxx to treat osteoarthritis, which affects more than 16 million Americans.
Instead of seeking indication for RA, which affects about 2 million Americans, it wants the FDA to approve Vioxx for acute pain treatment a market of more than 40 million Americans.
As new medications are relieving arthritis symptoms without upsetting stomachs, an Arthritis Foundation survey shows that misconceptions by both doctors and patients are holding people back from treatment that might help.
The Web site should improve access to what has long been a valuable resource for fighting the disease: the HIV/AIDS Treatment Directory, published since 1985 by the American Foundation for AIDS Research.
